IRRITABLE BOWEL SYNDROME – NEW PERSPECTIVE

Joanna Kulpa; Kornelia Tyczka; Marcin Szczepanik; Maria Nowakowska; Jakub Senko; Zofia Suchanek

doi:10.31435/ijitss.3(51).2026.6271

Authors

Joanna Kulpa Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0007-7057-6282
Kornelia Tyczka Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0000-0001-8700-2372
Marcin Szczepanik Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0004-0475-6187
Maria Nowakowska University Teaching Hospital No. 1 of the Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0007-2321-0464
Jakub Senko Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0006-2878-5737
Zofia Suchanek Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0003-6911-230X

DOI:

https://doi.org/10.31435/ijitss.3(51).2026.6271

Keywords:

Irritable Bowel Syndrome (IBS), Gut Microbiota, Gut-Brain Axis, Pathophysiology, Probiotics

Abstract

Background: IBS is a worldwide chronic gastrointestinal tract disorder. The challenges in treatment include unknown causes, non-specific symptoms, lack of precises testing, diagnosis based on ruling out other ailments. New therapies and probiotics show promise in improving the now available treatments and alleviating symptoms in a more precise manner based on IBS type. The understanding of the gut-brain axis as the basis of novel therapies shows promise in further implementation of more efficient treatment.

Aim: This narrative review analysis the new therapeutical possibilities and probiotic influence on IBS treatment and the gut-brain axis.

Material and methods: A search of relevant research databases was conducted to identify eligible papers.

Results: Management of IBS is still on insufficient level. Some studies showed the opportunities arising from the implementation of prostaglandines or even locally acting agonist of opioid receptors. Probiotics also play an important role. On the other hand, the pathophysiology of the disease and the interactions between hormones and cytokines still recuire further studies.

Conclusions: IBS is a complex medical condition, the usage of probiotics and other novel therapeutic agents may alleviate the severity of the disease.

References

Ozojide, K. O., Ozigbo, A. A., Ghartey, K. K., Okobi, O. E., Muoghalu, N., Gbagba, O. A., et al. (2025). Demographic and clinical epidemiology of irritable bowel syndrome in U.S. community health centers: A cross-sectional analysis of the 2022–2023 National Ambulatory Medical Care Survey. Cureus, 17(7), e87124.

Ballena-Caicedo, J., Valladolid-Sandoval, L. A. M., Zuzunaga-Montoya, F. E., & Vera-Ponce, V. J. (2025). Global prevalence of irritable bowel syndrome: An updated systematic review and meta-analysis. Gastroenterology Research, 18(6), 308–321.

Lucak, S. (2004). Diagnosing irritable bowel syndrome: What’s too much, what’s enough? MedGenMed, 6(1), Article 17.

Bonetto, S., Fagoonee, S., Battaglia, E., Grassini, M., Saracco, G. M., & Pellicano, R. (2021). Recent advances in the treatment of irritable bowel syndrome. Polish Archives of Internal Medicine, 131(7–8), 709–715.

Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics of North America, 46(1), 77–89.

Stilling, R. M., Dinan, T. G., & Cryan, J. F. (2014). Microbial genes, brain and behaviour: Epigenetic regulation of the gut-brain axis. Genes, Brain and Behavior, 13(1), 69–86.

Lagier, J. C., Dubourg, G., Million, M., Cadoret, F., Bilen, M., Fenollar, F., et al. (2018). Culturing the human microbiota and culturomics. Nature Reviews Microbiology, 16, 540–550.

Liu, Y. X., Qin, Y., Chen, T., Lu, M., Qian, X., Guo, X., et al. (2021). A practical guide to amplicon and metagenomic analysis of microbiome data. Protein & Cell, 12(5), 315–330.

Dinan, T. G., & Cryan, J. F. (2015). The impact of gut microbiota on brain and behaviour: Implications for psychiatry. Current Opinion in Clinical Nutrition and Metabolic Care, 18(6), 552–558.

Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., & Wang, R. F. (2019). Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis. Journal of Neuroinflammation, 16(1), Article 53.

Michel, L., & Prat, A. (2016). One more role for the gut: Microbiota and blood-brain barrier. Annals of Translational Medicine, 4(1), Article 15.

Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., et al. (2014). The gut microbiota influences blood-brain barrier permeability in mice. Science Translational Medicine, 6(263), 263ra158.

Malinen, E., Rinttilä, T., Kajander, K., Mättö, J., Kassinen, A., Krogius, L., et al. (2005). Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. The American Journal of Gastroenterology, 100(2), 373–382.

Bhattarai, Y., Muniz Pedrogo, D. A., & Kashyap, P. C. (2017). Irritable bowel syndrome: A gut microbiota-related disorder? American Journal of Physiology-Gastrointestinal and Liver Physiology, 312(1), G52–G62.

Shukla, R., Ghoshal, U., Ranjan, P., & Ghoshal, U. C. (2018). Expression of Toll-like receptors, pro- and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: The evidence for its micro-organic basis. Journal of Neurogastroenterology and Motility, 24(4), 628–642.

Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018). The brain-gut-microbiome axis. Cellular and Molecular Gastroenterology and Hepatology, 6(2), 133–148.

Hillestad, E. M. R., van der Meeren, A., Nagaraja, B. H., Bjørsvik, B. R., Haleem, N., Benitez-Paez, A., et al. (2022). Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome. World Journal of Gastroenterology, 28(4), 412–431.

Gao, J., Xiong, T., Grabauskas, G., & Owyang, C. (2022). Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell-prostaglandin E2. Gastroenterology, 162(7), 1962–1974.e6.

Gros, M., Gros, B., Mesonero, J. E., & Latorre, E. (2021). Neurotransmitter dysfunction in irritable bowel syndrome: Emerging approaches for management. Journal of Clinical Medicine, 10(15).

Neuhuber, W., & Wörl, J. (2018). Monoamines in the enteric nervous system. Histochemistry and Cell Biology, 150(6), 703–709.

Koumbi, L., Giannelou, M.-A., & Castelli, L. (2025). The gut–brain axis in irritable bowel syndrome: Neuroendocrine and epigenetic pathways. Academia Biology.

Raskov, H., Burcharth, J., Pommergaard, H. C., & Rosenberg, J. (2016). Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes, 7(5), 365–383.

Lambiase, C., Rettura, F., Sciumè, G. D., Tedeschi, R., Grosso, A., Cancelli, L., et al. (2025). Targeting γ-aminobutyric acid pathways in irritable bowel syndrome: Bridging central nervous system, enteric dysfunction, and the microbiota-gut-brain axis. Frontiers in Pharmacology, 16, Article 1677037.

Sahu, S. K., Nath, P., Mallick, B., Praharaj, D., Giri, S., Panigrahi, S. C., et al. (2025). Pharmacotherapy for chronic idiopathic constipation and constipation-predominant irritable bowel syndrome beyond conventional laxatives: A narrative review. Cureus, 17(11), e97523.

Akram, U., Rehman, O. U., Fatima, E., Nadeem, Z. A., Usman, O., Rasheed, W., et al. (2025). The efficacy of lubiprostone in patients with constipation: An updated systematic review and meta-analysis. JGH Open, 9(1), e70070.

Drossman, D. A., Chey, W. D., Johanson, J. F., Fass, R., Scott, C., Panas, R., et al. (2009). Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome—Results of two randomized, placebo-controlled studies. Alimentary Pharmacology & Therapeutics, 29(3), 329–341.

Johanson, J. F., Drossman, D. A., Panas, R., Wahle, A., & Ueno, R. (2008). Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics, 27(8), 685–696.

Chey, W. D., Lembo, A. J., & Rosenbaum, D. P. (2017). Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: A phase 2, randomized, placebo-controlled efficacy and safety trial. The American Journal of Gastroenterology, 112(5), 763–774.

Liu, R., & Staller, K. (2020). Update on eluxadoline for the treatment of irritable bowel syndrome with diarrhea: Patient selection and perspectives. Drug Design, Development and Therapy, 14, 1391–1400.

Brenner, D. M., Dove, L. S., Andrae, D. A., Covington, P. S., Gutman, C., & Chey, W. D. (2018). Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. Neurogastroenterology & Motility, e13331.

Camilleri, M., & Boeckxstaens, G. (2023). Irritable bowel syndrome: Treatment based on pathophysiology and biomarkers. Gut, 72(3), 590–599.

Ducrotté, P., Sawant, P., & Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology, 18(30), 4012–4018.

Quigley, E. M., & Flourie, B. (2007). Probiotics and irritable bowel syndrome: A rationale for their use and an assessment of the evidence to date. Neurogastroenterology & Motility, 19(3), 166–172.

O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017). Next-generation probiotics: The spectrum from probiotics to live biotherapeutics. Nature Microbiology, 2, Article 17057.

Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J., & Martinez-Medina, M. (2017). Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. The ISME Journal, 11(4), 841–852.

Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F., Pande, A., et al. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea-predominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled pilot clinical study. Nutrition Journal, 15, Article 21.